<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348099</url>
  </required_header>
  <id_info>
    <org_study_id>H14-02461</org_study_id>
    <nct_id>NCT02348099</nct_id>
  </id_info>
  <brief_title>Ultrasound Detection and Characterization of Subclinical Hypertrophy in Diabetes</brief_title>
  <official_title>Ultrasound Guided Detection and Characterization of Subclinical Lipohypertrophy in Type 1 and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to enroll 100 people to assess the incidence of lipohypertrophy as&#xD;
      detected with ultrasound and its impact on glycemic variability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipohypertrophy is a well documented phenomenon in patients with diabetes in which&#xD;
      hypertrophy and differentiation of adipocytes occurs in the dermal reticular layer at the&#xD;
      sites of subcutaneous insulin injection. Currently, lipohypertrophy is assessed by palpating&#xD;
      insulin injection sites. The detection on early, non palpable (subclinical) lipohypertrophy&#xD;
      remains difficult in the clinical setting. Recent studies have identified distinct&#xD;
      ultrasonographic features of hyperechogenicity in areas of adipose tissue consistent with&#xD;
      clinical evidence of lipohypertrophy at insulin injection sites, and have detected changes&#xD;
      int he thickness of subcutaneous tissue where not clinically evident in population of&#xD;
      patients with type 1 diabetes. Lipohypertrophy can adversely affect glycemic control.&#xD;
      Injecting into lipohypertrophic areas leads to poor absorption and the need for increasing&#xD;
      doses of insulin.&#xD;
&#xD;
      In this study study participants will undergo an assessment for lipohypertrophy during a&#xD;
      scheduled visit at the VGH Diabetes Centre. A Diabetes Nurse will assess lipohypertrophy by&#xD;
      palpation according to the FIT Protocol. A second diabetes nurse who was not present at the&#xD;
      palpation will assess insulin injection sites for lipohypertrophy by ultrasound using a&#xD;
      linear probe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Subclinical Lipohypertrophy</measure>
    <time_frame>Assessed one time only at the time of clinic visit</time_frame>
    <description>Lipohypertrophy seen on ultrasound but not felt by palpation</description>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes</condition>
  <condition>Lipohypertrophy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        People age 19 and over with type 1 or type 2 diabetes who take insulin to manage their&#xD;
        diabetes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19 years of age or older&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes&#xD;
&#xD;
          -  Using insulin to manage diabetes for at least 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Using insulin pumps, insulin secretagogues, Glucagon-Like Peptide-1 (GLP-1) agonists&#xD;
             to manage diabetes&#xD;
&#xD;
          -  Use of immunosuppressant agents&#xD;
&#xD;
          -  Women who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graydon Meneilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Graydon Meneilly</investigator_full_name>
    <investigator_title>Professor, UBC Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Lipohypertrophy</keyword>
  <keyword>Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

